Evaluation of the efficacy of Sitagliptin plus peginterferon alfa 2b /ribavirin combination therapy in CHC patients with insulin resistance

Evaluation of the efficacy of Sitagliptin plus peginterferon alfa 2b /ribavirin combination therapy in CHC patients with insulin resistance - ESPRIT study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003957

Enrollment

Registered

2010-08-01

Start date

2010-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C

Interventions

Dietary intervention(3 months before PEG/RIB treatment) Dietary intervention(3 months before PEG/RIB treatment) + sitagliptin 50mg Q.D.oral administration) from 3 month before PEG/RIB treatment to end

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: chronic hepatitis C Insulin resistance(HOMA&#8805;2) HCV viral load&#8805; 5 log copies/mL HCV genotype 1

Exclusion criteria

Exclusion criteria: 1) Pregnant , possibly pregnant or lactating women 2) Patients with severe heart diseases 3) Chronic kidney failure or creatinine clearance of <=50 mL/min 4) Current or history of severe psychiatric disorder 5) Autoimmune hepatitis 6) Intolerance to sitagliptin 7) medication for diabetes

Design outcomes

Primary

Measure	Time frame
SVR rate	—

Secondary

Measure	Time frame
HOMA-IR decrease safet	—

Countries

Japan

Contacts

Public ContactMasaki Saito

Hyogo College Of Medicine Division of Hepatobiliary and Pancreatic Diseases Department of Internal Medicine

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026